查看文章

BACKGROUND Dimebolin (latrepirdine), a compound with multiple potential drug targets, is being evaluated in clinical trials for the treatment of Alzheimer's disease (AD) and preliminary results suggest it can slow the disease process. There is also evidence that dimebolin directly improves aspects of cognition. Here we examined the acute effect of dimebolin on components of working memory in non‐human primates, young adult (11–17 years old) and aged (20–31 years old) rhesus macaques.

EXPERIMENTAL APPROACH The effects of dimebolin (3.9–118 µg kg⁻¹) on working memory, as measured by performance on delayed matching‐to‐sample (DMTS), were examined in the normal young adult monkeys and aged adult monkeys. All the monkeys studied were proficient in the performance of a computer‐assisted DMTS task. In a subsequent experiment in the same subjects, dimebolin was administered 15 …